Did Sarepta Therapeutics Just Unveil a Breakthrough?

As one of the leading genetic medicine companies on the planet, Sarepta Therapeutics is on the forefront of many nerdy advances. It was the first drug developer to earn U.S. Food and Drug Administration (FDA) approval for products treating Duchenne muscular dystrophy (DMD), a rare genetic disorder impacting muscle development. That portfolio is expected to generate full-year 2022 net revenue of at least $825 million.